Subscribe to NRx Newsletter

Investor Relations

NRx Pharmaceuticals is a clinical-stage, biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company’s lead program NRX-101, is an oral, fixed dosed combination of D-cycloserine and lurasidone, which targets the brain’s NMDA receptor. Please click here for more on our clinical trial status.

NRx Pharmaceuticals (Nasdaq: NRXP), formerly NeuroRx, is now traded on the Nasdaq Global Select Exchange.

Stock Data

NRX Pharmaceuticals Inc. (NRXP)
NASDAQNRXP
NASDAQNRXP
Detailed Quote
NASDAQNRXP

Recent News

Recent News (new)

For more news and articles, visit our news page.

Press Release
June 18, 2024

Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology Retired at a rank that is the civilian equivalent of a senior flag officer...

Press Release
June 10, 2024

The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intravenous ketamine and intranasal S-ketamine as the emerging standard of...

Press Release
May 28, 2024

Poster presentation of "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or...

Bottom Global Links (above footer)
NRx Communications

Subscribe to the NRx Mailing List